{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:26:38Z","timestamp":1768422398457,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022850","name":"Myovant Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clgc.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T07:42:31Z","timestamp":1679643751000},"page":"383-392.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Daniel J.","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Cookson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Saltzstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Tutrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Selby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.03.009_bib0001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2023.03.009_bib0002","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.2147\/OTT.S117176","article-title":"Androgen deprivation therapy as backbone therapy in the management of prostate cancer","volume":"9","author":"Merseburger","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2023.03.009_bib0003","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.03.009_bib0004","unstructured":"Prostate cancer, National Comprehensive Cancer Network Clinical Practice guidelines in oncology. 2022. Version 1. 2023. Available at: NCCN.org. Accessed December 18, 2022."},{"key":"10.1016\/j.clgc.2023.03.009_bib0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urology.2009.08.008","article-title":"Does oral antiandrogen use before luteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?","volume":"75","author":"Oh","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2023.03.009_bib0006","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2490-14-55","article-title":"Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)","volume":"14","author":"Gupta","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.clgc.2023.03.009_bib0007","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.med.45.1.391","article-title":"Gonadotropin-releasing hormone and its analogs","volume":"45","author":"Conn","year":"1994","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clgc.2023.03.009_bib0008","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ajur.2018.09.001","article-title":"Combination therapy with androgen deprivation for hormone sensitive prostate cancer: a new frontier","volume":"6","author":"Etheridge","year":"2019","journal-title":"Asian J Urol"},{"key":"10.1016\/j.clgc.2023.03.009_bib0009","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.03.009_bib0010","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.03.009_bib0011","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.03.009_bib0012","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.clgc.2023.03.009_bib0013","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.clgc.2023.03.009_bib0014","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2023.03.009_bib0015","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2023.03.009_bib0016","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2023.03.009_bib0017","year":"2020"},{"issue":"13","key":"10.1016\/j.clgc.2023.03.009_bib0018","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1002\/cam4.2442","article-title":"Phase I trial of TAK-385 in hormone treatment-na\u00efve Japanese patients with nonmetastatic prostate cancer","volume":"8","author":"Suzuki","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2023.03.009_bib0019","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1210\/jc.2015-2770","article-title":"Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): phase 1 study in healthy males","volume":"100","author":"MacLean","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.clgc.2023.03.009_bib0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"issue":"suppl 2","key":"10.1016\/j.clgc.2023.03.009_bib0021","article-title":"Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts)","volume":"34","author":"Saad","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clgc.2023.03.009_bib0022","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.03.009_bib0023","unstructured":"ORGOVYX (relugolix) tablets [Summary of Product Characteristics]. Brisbane, CA: Myovant Sciences, Inc.; Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orgovyx-epar-product-information_en.pdf. Accessed: January 26, 2023."},{"issue":"10","key":"10.1016\/j.clgc.2023.03.009_bib0024","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1023\/A:1026183200740","article-title":"P-glycoprotein increases from proximal to distal regions of human small intestine","volume":"20","author":"Mouly","year":"2003","journal-title":"Pharm Res"},{"key":"10.1016\/j.clgc.2023.03.009_bib0025","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.03.009_bib0026","series-title":"XTANDI (enzalutamide) [package insert]","year":"2022"},{"key":"10.1016\/j.clgc.2023.03.009_bib0027","series-title":"Taxotere (docetaxel) injection, for intravenous use [package insert]","year":"2021"},{"key":"10.1016\/j.clgc.2023.03.009_bib0028","article-title":"Coadministration of Apalutamide and Relugolix in Patients with localized prostate cancer at high risk for metastases","author":"Brown","year":"2022","journal-title":"Target Oncol"}],"updated-by":[{"DOI":"10.1016\/j.clgc.2023.12.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000}}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732300068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732300068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T15:11:20Z","timestamp":1734016280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732300068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S155876732300068X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.03.009","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.clgc.2023.12.006","asserted-by":"object"}]},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}